---
title: Masked Comparison of a New PEG Based Artificial Tear and Optive for Comfort, Vision & Wear Time in Patients Wearing Contact Lenses
nct_id: NCT00570843
overall_status: COMPLETED
phase: PHASE4
sponsor: Bp Consulting, Inc
study_type: INTERVENTIONAL
primary_condition: Comfort, Vision and Wear Time
countries: United States
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT00570843.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT00570843"
ct_last_update_post_date: 2010-02-22
last_seen_at: "2026-05-12T07:34:27.485Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Masked Comparison of a New PEG Based Artificial Tear and Optive for Comfort, Vision & Wear Time in Patients Wearing Contact Lenses

**Official Title:** Phase 4 Masked Comparison of a New PEG Based Artificial Tear and Optive for Comfort, Vision & Wear Time in Patients Wearing Contact Lenses

**NCT ID:** [NCT00570843](https://clinicaltrials.gov/study/NCT00570843)

## Key Facts

- **Status:** COMPLETED
- **Phase:** PHASE4
- **Study Type:** INTERVENTIONAL
- **Target Enrollment:** 50
- **Lead Sponsor:** Bp Consulting, Inc
- **Conditions:** Comfort, Vision and Wear Time
- **Start Date:** 2008-03
- **Completion Date:** 2010-02
- **CT.gov Last Update:** 2010-02-22

## Brief Summary

The objective of this study is to evaluate the effect of a new PEG based artificial tear as compared to Optive on comfort, wear time, and vision in patients wearing contact lenses.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** Yes

```
Inclusion Criteria:

* Use of soft contact lenses (e.g. silicone hydrogel lenses, daily disposables etc.) and multipurpose solution for cleaning, including enzyme-based cleaners (ClearCare etc.)
* Able to wear contact lenses for approximately 10-12 hours/day
* Willingness to complete entire length of trial and comply with subjective questionnaire.

Exclusion Criteria:

* Patients taking topical cyclosporine (Restasis)
* Patients currently using Optive for dryness relief.
* Patients wearing hard or rigid gas permeable lenses
* Patients with uncontrolled systemic disease which may confound the results of the trial.
```

## Arms

- **1.** (ACTIVE_COMPARATOR)
- **2.** (PLACEBO_COMPARATOR)

## Interventions

- **New PEG based artificial tear** (DRUG) — 1, 2, (in the eye) Instill one drop in the left eye or right eye four times daily (can be used more frequently if needed)
- **Optive** (DRUG) — 1, 2, (in the eye) Instill one drop in the left eye or right eye four times daily (can be used more frequently if needed)

## Primary Outcomes

- **Comfort** _(time frame: 1 month)_

## Secondary Outcomes

- **vision and wear time** _(time frame: 1 month)_

## Locations (1)

- The New York Presbyterian Hospital-Weill Cornell Medical College, New York, New York, United States

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.phases` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `outcomes.secondary` — added _(2026-05-12)_
- `armsInterventions.arms` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_
- `locations.the new york presbyterian hospital-weill cornell medical college|new york|new york|united states` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT00570843.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT00570843*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*